Research Article | Open Access
Effect of JumpstartMD, a Commercial Low-Calorie Low-Carbohydrate Physician-Supervised Weight Loss Program, on 22,407 Adults
Background. Commercial weight loss programs provide valuable consumer options for those desiring support. Several commercial programs are reported to produce ≥3-fold greater weight loss than self-directed dieting. The effectiveness of JumpstartMD, a commercial pay-as-you-go program that emphasizes a low-to-very-low-carbohydrate real-food diet and optional pharmacologic treatment without prepackaged meals or meal replacement, has not previously been described. Methods. Completer and last observation carried forward (LOCF) of clinic-measured weight loss (kg) in 18,769 female and 3638 male JumpstartMD participants. Results. Completers lost (mean ± SE) 8.7 ± 0.04 kg, 9.5 ± 0.04% with 44.5 ± 0.5% achieving ≥10% weight loss at 3 months (mo, N = 14,999 completers); 11.8 ± 0.1 kg, 12.6 ± 0.1% with 66.4 ± 0.6% achieving ≥10% weight loss at 6 mo (N = 11,805); and 11.5 ± 0.2 kg, 12.0 ± 0.2% with 57.6 ± 0.9% achieving ≥10% weight loss at 12 mo (N = 8514). LOCF estimates were −6.5 ± 0.03 kg, −7.2 ± 0.03% with 27.1 ± 0.3% achieving ≥10% weight loss at 3 mo; −7.7 ± 0.04 kg, −8.5 ± 0.04% with 36.3 ± 0.3% achieving ≥10% weight loss at 6 mo; and −7.7 ± 0.1 kg, −8.4 ± 0.1% with 34.6 ± 0.3% achieving ≥10% weight loss after 12 mo. Frequent health coach meetings was a major determinant of weight loss, with women and men attending ≥75% of their weekly appointments losing 8.8 ± 0.04 and 11.9 ± 0.1 kg, respectively, after 3 mo, 13.1 ± 0.1 and 16.5 ± 0.3 kg after 6 mo, and 16.5 ± 0.3 and 19.4 ± 0.8 kg after 12 mo. Phentermine and phendimetrazine had a minor effect in women only at 1 (6.1% greater weight loss than untreated), 2 (4.1%), and 3 mo (1.2%), but treated patients showed longer enrollment than nontreated during the first 3 (females: +0.4 ± 0.01; males: +0.3 ± 0.04 mo), 6 (females: +1.1 ± 0.04; males: +1.0 ± 0.1 mo), and 12 mo (females: +2.7 ± 0.1; males: +2.4 ± 0.2 mo). JumpstartMD produced generally greater weight loss than published reports for other real-food and prepackaged-meal commercial programs and somewhat greater or comparable losses to meal replacement diets. Conclusion. A one-on-one medically supervised program that emphasized real low-carbohydrate foods produced effective weight loss, particularly in those attending ≥75% of their weekly appointments.
Seventy percent of US adults are overweight or obese , 42% report trying to lose weight, and 23% report trying to maintain weight annually . Five to ten percent weight loss produces clinically significant health benefits , with even greater health benefits likely to accrue with greater weight loss .
Americans spend 2.5 billion dollars annually on commercial weight loss programs, broadly categorized as calorie-counting, food choice, and meal plans (e.g., Weight Watchers, Slimming World, Rosemary Conley, Biggest Losers Club, Metabolic Balance Nutrition Program and Itrim), prepackaged meals (e.g., Jenny Craig and Diet Chef), and meal replacement products including liquid shake diets (e.g., Nutrisystem, Medifast, Health Management Resource, and Itrim). Weight Watchers represent 45% of market, Nutrisystem 14%, and Jenny Craig 13%, with a number of other programs making up the remaining share . Slimming World and Rosemary Conley are available as online programs in the United States. In Europe, Australia, and some US states, partnerships exist between national payers and these programs for patients seeking weight loss. Several commercial programs have been shown to produce twice as much weight loss as those administered through standard healthcare settings [6, 7], and ≥3-fold greater weight loss than self-directed dieting [8, 9]. The odds for >10% weight loss in obese NHANES participants trying to lose weight were 70% greater for those that joined a commercial weight loss program vs. self-directed weight loss .
JumpstartMD’s approach to weight management uses a real-food low-to-very-low-carbohydrate diet and one-on-one, personalized instruction and support from trained health counselors in the setting of a medical clinic. It is an alternative to other commercial calorie-counting and meal plan programs that use group education and group support. This report presents weight loss data from over 20,000 self-paying adults who participated in the JumpstartMD program in the San Francisco Bay Area between 2007 and 2017. Uncontrolled longitudinal patient data have previously been reported in peer-reviewed journals for Weight Watchers [11–14], Slimming World [12, 13, 15–22], Rosemary Conley [12, 13], Jenny Craig [23, 24], Biggest Loser Club , Itrim , Metabolic Balance Nutrition Program , Medifast [28, 29], and Health Management Resources . Mean weight loss for JumpstartMD patients are compared to the published weight losses of other commercial programs, taking into account covariates reported to affect weight loss success: BMI, sex, and age.
JumpstartMD is a pay-as-you-go weight management program supervised by physicians that emphasizes the benefits of a low-carbohydrate diet and healthy lifestyle. Through weekly one-on-one clinic visits personalized to fit each person’s life and by emphasizing fresh, whole, nonpackaged foods, JumpstartMD’s health coaches provided accountability and support, nutritional guidance, behavioral modification, and fitness recommendations to achieve sustainable wellness goals. Because the program is medically supervised and a licensed healthcare practitioner is present in every center, JumpstartMD is also capable of making adjustments in diabetes, blood pressure, and other medications as well as offering FDA-approved weight loss medications for interested and eligible patients. Participants attended the program for as long as they wished.
Weight loss was achieved through nutritional guidance, tracking, and meal planning to create caloric deficits for sustained weight loss without the use of prepackaged foods or meal replacements. Clinicians prescribed a recommended nutritional guide path for members early in their program that eliminated consumption of grains, starches, and sugars while limiting consumption of carbohydrates to typically under 50 grams a day from low glycemic (nonstarchy) vegetables and fruits. Dietary carbohydrate recommendations varied by participant based on starting weight and degree of insulin resistance as noted from baseline laboratory tests. Structured meal plans were prescribed using portion sizes. Following the recommendations provided, participants’ energy intake derived from carbohydrate would typically fall between 10% and 20%, and sometimes as low as 5%. While JumpstartMD does not specifically “count calories” or discuss “calories consumed,” properly followed, the program would typically generate a dietary caloric deficit on the order of 500 to 1000 Calories or more per day.
Dietary compliance was tracked using the program’s pocket-sized forms or the participant’s own mobile phone-based software, which were reviewed weekly with their health coach or clinician. Dietary carbohydrate intake was monitored by measuring and recording amounts of approved fruits and vegetables consumed. Dietary protein consumption was similarly monitored by measuring and recording consumption of foods with high protein content, including meats and seafoods, dairy products, and legumes. Healthy dietary fats were tracked and monitored only when the food’s primary macronutrient composition was fat (i.e., as in the case of butter, cream, olive oil, nuts, seeds, and avocado). Dietary tracking was an important component of the intervention but was not collected in a standardized manner for data analysis.
Physical activity recommendations generally correspond to current Centers for Disease Control (CDC) recommendations while also supporting the patient’s own physical activity goals. Weights were measured directly at each clinic visit in light clothing without shoes (Tanita digital healthcare scales; Arlington Heights, IL). Participants were provided a macronutrient tracking tool to help them record their daily consumption of allotted carbohydrate, protein, and healthy fat servings. Participants reviewed their progress in achieving their macronutrient recommendations with their individual JumpstartMD clinician or health coach via weekly one-on-one in person visits. The program has expanded from a single clinic in 2007 to thirteen clinics across the greater San Francisco Bay Area.
2.1. Statistical Analysis
Anonymized data were provided to an independent statistician not previously associated with the commercial program for analysis. Attendance was calculated at each visit as the ratio of the number of follow-up appointments attended divided by the expected number of weekly appointments (i.e., number of days since baseline starting date divided by seven). For each individual, average number of days since baseline, weight loss, % weight loss, BMI change, attendance, and ≥5% and ≥10% weight loss were calculated within each two-week interval since baseline. Mean changes from baseline ± SE were calculated over all subjects within each interval and plotted vs. the average follow-up duration. Regression analyses were used to assess the relationship between weight loss vs. attendance, baseline BMI, sex, and age. Analysis of covariance was used to assess weight loss differences between patients on and off obesity drugs, with and without adjustment for enrollment duration. Results are presented with standard deviations given in parentheses “(SD)” or ±standard errors (±SE). Standard errors were reported because they represent the precision of the estimates (standard deviations can be computed by multiplying the SE by the square root of the sample size). Last observation carried forward (LOCF) included all subjects with follow-up weights and was calculated at 3, 6, 9, and 12 months. Interpolation was used to estimate results for completers at 1 month (30.4 days), 3 months (91.25 days), 6 months (182.5 days), 9 months (273.75 days), and one year (365 days). High-attendance completers were defined as patients attending at least 75% of their weekly appointments, as has been defined by others [14, 22, 30]. All analyses were performed using JMP version 13.2.0 (SAS institute, Cary, NC). Race, socioeconomic status, and comorbidity data were not collected.
2.2. Comparison with Other Published Studies
JumpstartMD weight losses were compared to those reported for other commercial programs (Weight Watchers [6, 8, 11–14, 31–42], Slimming World [12, 13, 15–22, 37, 43], Rosemary Conley [12, 13, 37, 42], Biggest Losers Club [25, 44, 45], eDiet [46, 47], Jenny Craig [23, 24, 33, 48–50], Itrim , Nutrisystem [9, 33, 51–53], Medifast [28, 29, 54–56], Health Management Resources [30, 57–59], Metabolic Balance Nutrition Program , and Diet Chef ) when matched for follow-up duration, BMI eligibility, age, proportion of males, and sex-specific baseline BMI effects. The studies were identified from systematic reviews, PubMed searches by program name, and references cited within each paper retrieved (Table 1). We excluded studies that used commercial weight loss products but were directed by others (e.g., Slimfast and Optifast) because they lacked standardized behavioral interventions. We also excluded very-low-calorie diets, studies conducted before the year 2000, studies not reporting LOCF or completers, and studies in cancer survivors.
Abbreviations: HMR: Health Management Resources; JC: Jenny Craig; NHS: National Health Service; RC: Rosemary Conley; RT: randomized trial; SW: Slimming World; and WW: Weight Watchers. ∗Mean (standard deviation).
Results are presented in as forest plots with diamonds representing the average differences between JumpstartMD and other commercial programs (identical size for each comparison) and 95% confidence intervals for the differences. Standard errors (SE) were taken from the published reports, calculated as SD/N0.5, or calculated from the 95 percent confidence intervals as (upper-lower bound)/(). When SEs were not otherwise available, the standard deviations were estimated from the relationship between mean weight change (independent variable) and the standard deviation of weight change (dependent variable) from the JumpstartMD dataset, using the coefficients of Table 2. Different coefficients were used for estimating “LOCF” and “completer” standard deviations. Median weight losses [11, 14, 32] were increased by 5.2% for weight change (∆kg), 2.1% for percent weight change (∆%), and 4.4% for BMI change (∆kg/m2) corresponding to the JumpstartMD difference between mean weight loss and median weight losses.
2P ≤ 0.05.
2.3. Statistical Methods, LOCF
The primary outcome for comparing JumpstartMD to other commercial programs was LOCF because it encapsulates both retention and weight loss success. Differences in design and analyses have stymied prior efforts to synthesize commercial weight loss results by meta-analyses . Our analyses adjust for these differences by tailoring the JumpstartMD sample to the recruitment specifications and follow-up duration of each published report. Specifically, adjusted JumpstartMD LOCF weight losses (mean ± SEprediction) were calculated to corresponding to the average baseline BMI, age, and proportion of men of each commercial program. This was done by (1) restricting the JumpstartMD data to the commercial study’s BMI recruitment range and (2) applying multiple linear regression to the restricted JumpstartMD LOCF data with age, male sex, and sex-specific baseline BMI effects as independent variables. Prediction formulas for the expected value and the prediction standard errors were then evaluated using the average age, sex, and BMI for the reported study (Table 1). The mean differences between JumpstartMD and the reported commercial studies and the standard error for the difference were estimated by standard methods.
The JumpstartMD LOCF analysis included only those subjects who chose to continue their program beyond their initial assessment visit. Some published studies assigned zero weight loss to patients without any follow-up data, affecting the denominator but not the numerator of the average LOCF. Ahern et al. reported that the proportion of the sample lacking follow-up data was 5.35% (1570/29326) , Aston et al. reported 7.0% (74/1058) , Heshka et al. 6.1% (13/211) , Stubbs et al. 6.8% out of 1.43 million , Martin et al. approximately 6% out of 81,505 , Furlow and Anderson reported 5.9% (12/204) , Hutchesson et al. reported 2.2% for standard and 2.4% for fast-track challenge , and 2.2% standard rate assumed to apply to Collins et al. . Avery et al. reported 997 of 1020 Healthy Living Pharmacy patients and 5306 of 5482 general practitioner patients returned for follow-up weigh-ins . Therefore, to achieve comparability to the JumpstartMD results, the reported estimates from other studies were adjusted upwards by decreasing their denominator by the proportion of the sample that lacked follow-up (assumed to be 7% unless otherwise stated [6, 12, 20, 37]). An anomaly was Mitchell et al. who reported 25.7% non-follow-up among 1605 Medicaid recipients, which may be due to the lower socioeconomic status or racial composition of their sample . To obtain corresponding samples, JumpstartMD LOCF data were calculated for patients attending ≥4 weeks for comparison with Meffert and Gerdes .
The recruitment criteria for subsidized physician referrals were generally ≥30 kg/m2, but exceptions could be made per the physician’s discretion . Therefore, for comparisons with subsidized physician referrals, the JumpstartMD sample included randomly selected overweight patients (25 < BMI < 30) to match their reported recruitment proportion (assumed to be 4% as reported by Dixon et al.  unless otherwise specified).
Follow-up duration was taken as that described by the commercial study, i.e., 84 days if described as 12-week weight loss, 91.25 days if described as 3-month weight loss, or if otherwise described (e.g., 12 meetings or until a 5-week hiatus ). Although the 12 weekly Weight Watcher or Slimming World meetings represent only 11-week differences, patients apparently had 14 weeks to complete the course [20, 21] and therefore were compared to 12-week JumpstartMD weight changes.
2.4. Statistical Methods, Completers
JumpstartMD completer weight losses were compared to those reported for other commercial studies when matched for follow-up duration, recruitment BMI range, baseline age, proportion of males, and sex-specific baseline BMI effects as described in Methods section. Specifically, we (1) selected the JumpstartMD subset corresponding to the BMI range of the other commercial program, (2) divided the JumpstartMD records into 2-week intervals, (3) obtained the regression coefficients for expected weight loss and SEprediction within each interval by least-squares regression with age, sex, and sex-specific effects of baseline BMI as independent variables, (4) within each interval, used these regression coefficients to calculate the expected weight loss and SEprediction corresponding to the average baseline age, sex, and BMI of the other commercial program, and (5) used linear interpolation to estimate weight loss for the designated length of follow-up from the proximal 2-week intervals. Comparisons are presented as “(JumpstartMD ± SEprediction vs. other commercial program ± SE).” In some cases [13, 43, 44, 50, 60], weight loss for completers was calculated from baseline observation carried forward (BOCF) by inflating the BOCF weight loss by the ratio of the total sample divided by the number of patients providing data (i.e., zero weight loss in patients lost to follow-up increases the denominator but not the numerator in calculating mean weight loss).
Completers were usually defined as participants with a weight measurement at a specified follow-up duration; however, Stubbs et al. defined “completers” as completing 10th, 11th, or 12th visit by the 14th week  and the 20th, 21st, 22nd, 23rd, or 24th visit by the 28th week . Aherns et al. defined completers as completing 12 visits or the last observation until a 5-week hiatus in attendance . JumpstartMD completers were correspondingly defined for comparisons with these studies. Additional adjustments for the inclusion of non‐obese patients and the estimation of 12-week follow-up for Weight Watchers and Slimming World were as described above for LOCF.
Pooled estimates were calculated as weighted averages of the inverse of the standard error2 (fixed effect meta-analysis).
Of the 24,395 patients in the electronic patient base, we excluded 114 for errors in the admission date (prior to Jan 1, 2007) or missing sex information and 59 for missing baseline body weights. Of the 24,222 patients remaining, we excluded 1815 (7.5%) patients who received an initial evaluation and weight loss recommendations but chose not to enroll with the program, leaving 22,407 patients for the analysis of weight change.
Women represented 83.8% of the participating patient population. On average, they were slightly younger than the men (mean (SD): 51.8 (12.0) vs. 53.7 (12.4) years, ), including a higher percent (±SE) under 40 years (women vs. men: 15.6 ± 0.3 vs. 12.9 ± 0.6%), and between 40 and 64 years (70.2 ± 0.3 vs. 67.4 ± 0.8%), and a lower proportion 65 years and older (14.1 ± 0.3 vs. 19.7 ± 0.7%). Women also had lower BMI than men (31.2 (5.8) vs. 34.3 (5.3) kg/m2, ). For the sexes combined, 10.1% were healthy weight, 33.9% overweight, 31.1% Class I (30 ≤ BMI < 35 kg/m2), 15.2% Class II (35 ≤ BMI < 40 kg/m2), and 9.5% Class III obese (BMI ≥ 40 kg/m2).
Figure 1(a) shows that approximately two-third of the 18,769 women (67.2%) and 3638 men (65.6%) attended ≥3 months, 53.4% of the women and 49% of the men attended ≥6 months, 45.2% of the women and 39.4% of the men attended ≥9 months, and 39.2% of the women and 31.8% of men attended for ≥one year. Regression analyses showed that during the first 3, 6, 9, and 12 months, women were enrolled an average ± SE of 1.2 ± 0.5, 4.9 ± 1.2, 10.3 ± 2.0, and 16.4 ± 2.7 days longer than men, respectively, and each year of age was associated with 0.17 ± 0.01, 0.47 ± 0.04, 0.81 ± 0.06, and 1.12 ± 0.08 days additional enrollment, respectively. The effects of BMI on enrollment duration were not significant at 9 and 12 months.
Figure 1(b) displays the intensity of participation as measured by clinic attendance. Among completers, the percent of patients attending at least 50%, 60%, 75%, and 90% of clinic appointments was 95.1%, 90.8%, 78.0%, and 45.9% during the first three months, respectively; 89.5%, 82.7%, 62.6%, and 24.6% during the first six months, respectively; 80.3%, 68.9%, 45.1%, and 27.6% during the first nine months, respectively; and 66.5%, 53.3%, 30.8%, 8.3% for the year (percentages are the cumulative average attendance through the patient’s last visit). Regression analyses showed that during the first 3, 6, 9, and 12 months, percent attendance averaged ± SE 2.10 ± 0.43%, 4.0 ± 0.65%, 3.49 ± 0.93%, and 5.40 ± 1.17% higher in women than men, respectively, and averaged 0.30 ± 0.03%, 0.76 ± 0.0.04%, 1.09 ± 0.06%, and 1.34 ± 0.07% higher per kg/m2 increment in BMI, respectively. Age was not significantly related to attendance.
3.3. Weight Loss in Completers
Figure 2 presents the average weight loss in completers regardless of their level of active participation or starting weight. At the end of the first month, the patients lost an average of 4.37 ± 0.02 kg and 4.86 ± 0.02% of body weight and 1.57 ± 0.01 kg/m2 of BMI. Nearly one-half (46.59 ± 0.33%) had lost over 5% of their body weight. At the end of 13 weeks, the patients lost an average of 8.66 ± 0.04 kg body weight, representing a 9.47 ± 0.04% reduction, and a 3.12 ± 0.01 kg/m2 drop in BMI, with 86.3 ± 0.31% attaining ≥5% and 44.51 ± 0.45% attaining ≥10% weight loss. After 6 months (26 weeks), the completers had lost 11.81 ± 0.08 kg, 12.57 ± 0.08% of baseline weight, and 4.28 ± 0.03 kg/m2. Ninety percent (89.73 ± 0.37%) had lost over 5% and 66.37 ± 0.58% had lost over 10% of body weight. Thereafter, weight loss leveled off, with those completing 9 months (39 weeks) averaging 12.39 ± 0.13 kg weight loss, 12.96 ± 0.12% weight loss, and 4.52 ± 0.05 kg/m2 reduction in their BMI from baseline. Five percent or greater weight loss was attained by 87.13 ± 0.52% of the sample and 10% or greater weight loss by 65.32 ± 0.74% of completers. Similarly, at one year, average weight loss was 11.45 ± 0.16 kg, 11.98 ± 0.16%, and 4.22 ± 0.06 kg/m2 with 81.37 ± 0.70% losing ≥5% body weight and 57.57 ± 0.89% weight loss losing ≥10% body weight. Figure 3 shows that the amount of weight loss was strongly related to baseline BMI.
Figure 4 shows that weight loss success depended on regular meetings with the patients’ health counselor. Figure 4(a) shows the relationship between attendance and weight loss for months 1 through 9 and at one year. At each time point, greater attendance was significantly associated with greater weight loss. Moreover, there was a significant curvilinear relationship between attendance and weight loss, which became progressively greater over time. This meant that the difference between low and high attendees became greater over time, such that at 40% attendance, weight loss plateaued after 4 months, whereas at 80% attendance, weight loss continued longer into the year. Those meeting with their health counselor nearly every week showed the greatest total weight loss and the longest period of active weight loss.
This is further illustrated by Figure 4(b) showing average weight loss in those who made at least three-quarters of the weekly appointments with their healthcare counselors (high attendees) vs. those who made less than half (low attendees). The high attendees had approximately twice the weight loss as low attendees at three (females: 8.83 ± 0.04 vs. 4.97 ± 0.21; males: 11.9 ± 0.14 vs. 6.84 ± 0.56 kg), six (females: 13.13 ± 0.11 vs. 6.21 ± 0.27; males: 16.51 ± 0.31 vs. 10.09 ± 0.71 kg), nine (females: 15.42 ± 0.21 vs. 6.32 ± 0.25; males: 18.61 ± 0.54 vs. 10.20 ± 0.95 kg), and twelve months (females: 16.49 ± 0.31 vs. 6.03 ± 0.23; males: 19.35 ± 0.81 vs. 8.39 ± 0.67 kg). High attendance was associated with somewhat greater baseline BMI than low attendance (31.73 ± 0.04 vs. 30.92 ± 0.06 kg/m2), but little difference in age (52.0 ± 0.09 vs. 52.8 ± 0.12 years) or sex (84.0 ± 0.3% vs. 85.0 ± 0.4% female).
3.4. Last Observation Carried Forward (LOCF)
JumpstartMD LOCF weight loss estimates were 6.51 ± 0.03 kg, 7.21 ± 0.03%, and 2.35 ± 0.01 kg/m2, with 65.9 ± 0.32% attaining ≥5% and 27.1 ± 0.30% attaining ≥10% weight loss after 13 weeks; 7.70 ± 0.04 kg, 8.45 ± 0.04%, and 2.79 ± 0.01 kg/m2, with 66.7 ± 0.32% achieving ≥5% and 36.6 ± 0.33% attaining ≥10% weight loss after 26 weeks; 7.84 ± 0.05 kg, 8.56 ± 0.05%, and 2.84 ± 0.02 kg/m2, with 65.7 ± 0.32% achieving ≥5% weight and 36.3 ± 0.33% attaining ≥10% weight loss after 39 weeks; and 7.67 ± 0.05 kg, 8.36 ± 0.05%, and 2.78 ± 0.02 kg/m2, with 64.5 ± 0.32% attaining ≥5% and 34.6 ± 0.32% attaining ≥10% weight loss after 52 weeks. Regression analysis of LOCF showed that during the first 3, 6, 9, and 12 months, weight loss averaged (±SE) 1.69 ± 0.08, 1.46 ± 0.11, 1.29 ± 0.12, and 1.17 ± 0.12 kg less in women than men, respectively; 0.007 ± 0.002, 0.020 ± 0.003, 0.023 ± 0.004, and 0.025 ± 0.004 kg more per year of age, respectively; and 0.24 ± 0.01, 0.36 ± 0.0.01, 0.41 ± 0.01 and 0.42 ± 0.01 kg more per increment in baseline BMI, respectively. These analyses represent the independent effect of each factor. The male-female difference increased when adjusted for enrollment duration and attendance (i.e., 1.89 ± 0.06 kg greater weight loss in men than women at 13 weeks, 1.90 ± 0.08 kg at 26, 1.84 ± 0.10 kg at 39 weeks, and 1.72 ± 0.10 kg at 52 weeks).
3.5. Weight Loss Drugs
Phentermine and phendimetrazine showed little effect on weight loss in completers except in women during the first two months of treatment. Patients prescribed these drugs were more likely to be females (23.7%) than males (17.4%), younger (prescribed vs. non-prescribed mean ± SE, female: 51.0 ± 0.17 vs. 52.0 ± 0.10; male: 51.0 ± 0.46 vs. 54.2 ± 0.23 years), and were slightly leaner if female (30.82 ± 0.08 vs. 31.29 ± 0.05 kg/m2, ) but not male (34.31 ± 0.22 vs. 34.26 ± 0.10 kg/m2). Among female completers, those prescribed phentermine or phendimetrazine lost 6.1% more weight by the end of the first month (difference±SE: −0.24 ± 0.04 kg, ) and 4.1% more weight by the end of the second month (−0.26 ± 0.06 kg, ), but only 1.2% more weight loss after 3 months (−0.10 ± 0.09 kg, nonsignificant), and no significant weight loss advantage thereafter. However, retention was greater in those prescribed weight loss drugs. Specifically, the pharmacologically treated patients showed longer average enrollment than the untreated during the first three (females: 2.51 ± 0.01 vs. 2.14 ± 0.01; males: 2.52 ± 0.03 vs. 2.20 ± 0.02 months), six (females: 4.49 ± 0.03 vs. 3.41 ± 0.02; males: 4.48 ± 0.07 vs. 3.50 ± 0.04 months), nine (females: 6.18 ± 0.04 vs. 4.31 ± 0.03; males: 6.10 ± 0.12 vs. 4.37 ± 0.04 months), and twelve months (females: 7.73 ± 0.06 vs. 5.07 ± 0.03; males: 7.48 ± 0.16 vs. 5.08 ± 0.07 months). Correspondingly, those prescribed drugs showed greater LOCF weight loss after three (females: 7.01 ± 0.06 vs. 5.83 ± 0.04; males: 9.18 ± 0.35 vs. 8.43 ± 0.11 kg), six (females: 8.66 ± 0.09 vs. 6.84 ± 0.05; males: 11.15 ± 0.41 vs. 9.64 ± 0.14 kg), nine (females: 8.98 ± 0.10 vs. 6.93 ± 0.05; males: 11.19 ± 0.42 vs. 9.79 ± 0.15 kg), and 12 months than nonusers (females: 8.81 ± 0.11 vs. 6.78 ± 0.05 kg; males: 10.73 ± 0.42 vs. 9.59 ± 0.15 kg). Adjustment for enrollment eliminated the LOCF weight loss difference between drug users and nonusers after three (unadjusted vs. adjusted difference ± SE, female: −1.18 ± 0.07 difference reduced to −0.18 ± 0.06 kg difference when adjusted, male: −0.76 ± 0.29 reduced to +0.46 ± 0.25 kg), six (female: −1.83 ± 0.10 reduced to −0.03 ± 0.08 kg, male: −1.51 ± 0.36 reduced to +0.57 ± 0.31 kg), nine (female: −2.05 ± 0.11 reduced −0.02 ± 0.10 kg, male: −1.40 ± 0.38 reduced to +1.00 ± 0.34 kg), and twelve months (female: −2.02 ± 0.11 reduced to −0.02 ± 0.10 kg, male: −1.13 ± 0.38 reduced to +0.99 ± 0.36 kg).
3.6. Weight Loss Prediction
Several studies suggest that rapid initial weight loss predicts longer-term weight loss [20–22, 26, 62]. Weight loss during the first 2 weeks was significantly correlated with LOCF weight loss at three (r = 0.62), six (r = 0.52), nine (r = 0.49), and twelve months (r = 0.47).
3.7. Comparison of LOCF with Other Commercial Programs
Figures 5 through 15 present the individual weight loss differences between JumpstartMD and other commercial studies when matched for follow-up duration, recruitment BMI, baseline age, proportion of males, and sex-specific baseline BMI effects. Negative differences for Δweight loss, Δ% weight loss, and ΔBMI represent greater weight loss in JumpstartMD patients. The average fixed effect meta-analysis estimates of the weight loss differences between JumpstartMD and these other programs are presented in Table 3. JumpstartMD weight losses were significantly greater than the average published losses over all calorie/food/meal plan (Weight Watchers, Slimming World, Rosemary Conley, and Itrim), and Internet programs (Biggest Loser Club) for all measures of weight loss (Table 3, Figures 5–15).
Negative values means greater JumpstartMD weight loss for ∆weight, ∆%weight, and ∆BMI, positive values means greater JumpstartMD weight loss ≥5% and ≥10% weight loss. Individual study results are presented in Figures 5–15. 1Weight Watchers [6, 8, 11–14, 31–42], Slimming World [12, 13, 15–17, 20–22, 37, 43], Rosemary Conley [12, 13, 37, 42], and Itrim . 2Biggest Loser Club [25, 44, 45] and Ediet [46, 47]. 3Metabolic Balance Nutrition Program (similar to JumpstartMD) . 4Jenny Craig [23, 24, 3 and 3, 48–50] Diet Chef . 5Nutrisystem [9, 33, 51–53], Medifast [28, 29, 54–56], Itrim , and Health Management Resources [30, 57–59].
Except for percent weight loss at 52 weeks, JumpstartMD weight loss was also greater than those reported for prepackaged meals (Table 3). Figure 16 (top panel) shows that one-year LOCF percent weight loss was greater for JumpstartMD than Jenny Craig self-paying customers for their Platinum (49% greater percent weight loss) and Rewards program (30% greater ). They also reported the Rewards program percent weight loss by final week of attendance . JumpstartMD LOCF weight loss was over 30% greater through the 39th week and 13% greater between weeks 40 and 52.
JumpstartMD weight loss was almost always greater than those reported for meal replacement programs in completers due to the inclusion of a very large sample of Nutrisystem completers . JumpstartMD kg weight loss was 18% greater than reported for 103,693 Nutrisystem patients at 3 months and 9% greater than reported for 32,280 patients at 6 months (Figure 11). These data are not included in the LOCF analyses or the completer’s analysis at 1 year. The figures suggest that Medifast 5&1 plans produced significantly less weight loss than JumpstartMD in the study by Shikany et al. , greater weight loss in the study by Coleman et al. , and mixed results in the study by Davis et al. . Medifast 4&2&1 plan and Health Management Resources (combination of meal replacement and prepackaged meals) showed significantly greater weight loss than JumpstartMD.
Although eighty percent of weight loss attempts are self-directed , commercial weight loss programs provide valuable consumer options for those desiring support. Our analyses of completers show that a medically supervised real-food, low-calorie, low-carbohydrate diet provided through a one-on-one in person behavioral intervention produced substantial average weight losses after 3 (8.7 kg or 9.5%), 6 (11.8 kg or 12.6%), and 12 months (11.5 kg or 12%). Five percent weight loss was achieved by 86.3% of JumpstartMD patients after 3 months, 90% after six months, and 81% after one year, over twice the weight loss identified by the FDA as an effective product (thirty-five percent achieving ≥5% weight loss ). Even greater average weight losses were attained in patients who attended at least 75% of their week appointments with their personal healthcare coach after 3 (women: 8.8 kg; men: 11.9 kg), 6 (women: 13.1 kg; men: 16.5 kg), and 12 months (women: 16.5 kg; men: 19.35 kg). Consistent with other reports , the weight loss tended to be rapid initially, diminishing thereafter, and then plateau as compensatory mechanisms that tend to increase food intake and reduce weight loss kick in. However, Figure 4 showed weight loss continued to be accrued throughout the year at higher participation levels. This is consistent with other reports showing the importance of patient involvement [8, 11, 14, 19–22, 27, 28, 32, 34–36, 40, 41, 45, 46].
The JumpstartMD results are consistent with other studies showing age [11, 19], sex [11, 12, 15, 19–22, 29, 30], and initial body weight [11, 12, 20, 21, 26, 42] affect weight loss success. The greater weight loss in heavier subjects may account in part for the greater weight loss success in men given that the sex difference largely disappeared for percent weight loss (Figure 2).
A one-on-one physician-supervised program that provides individual health counselors and nutritional advice must necessarily be more expensive than group-based and Internet-based therapies, and this additional cost warrants scrutiny in terms of weight loss success. Moreover, although important health benefits accrue for 5% or 10% weight loss, those seeking treatment frequently aspire to ≥25% weight loss and are more likely motivated by appearance rather than health .
Our comparative analyses were restricted to the intervention arm of the randomized trial (representing only 0.3% of the published patient population) and longitudinal patient data (99.7% of the published patient population) because we believe these uncontrolled values accurately reflect the treatment effects. Specifically, in the absence of illness or behavioral change, large cohorts of individuals do not lose weight over time, with most Western adults gaining 0.2 to 2.0 kg per annum [66, 67]. None of the wait-listed or usual diet control arms of commercial programs RCT show any significant weight loss, i.e., weight change from baseline: −0.3 ± 0.35 kg , +0.16 ± 0.88 kg , +0.84 ± 0.41 kg , +0.36 ± 0.24 kg , −0.25 kg , and −0.6 ± 0.71 kg . In addition, clinical trial participants are not representative of the general population, do not pay for their own treatment (selection bias), and are subtly coerced to participate and not dropout (performance bias). Hence, the call for “naturalistic studies” of large cohort followed prospectively that report retention rates and weight loss at discontinuation .
With one notable exception, the comparative analyses of Table 3 show that JumpstartMD patients lost greater weight than reported for other calorie-counting, food choice, and meal plans (Weight Watchers, Slimming World, Rosemary Conley, and Itrim). JumpstartMD kg weight loss was 53% greater at 12-13 weeks, 84% greater at 24–26 weeks, and 75% greater at 1 year than reported for other commercial calorie-counting programs for LOCF analyses and approximately 2-fold greater in completers analyses. Compared to Internet-based commercial programs (Biggest Losers Club, E-diet), JumpstartMD weight loss averaged approximately 1.5-fold greater for LOCF and 1.75-fold greater for completers. The notable exception is the Metabolic Balance Nutrition Program , a program similar to JumpstartMD in providing low-carbohydrate diet through individualized food lists and meal plans and individual support by certified advisors. We interpret the consistent weight losses reported for JumpstartMD in this report and the Metabolic Balance Nutrition Program as evidence that our approach is replicable across programs.
Jenny Craig (Jenny Craig, Inc; Carlsbad, CA) uses individual counseling, 1200–2000 kcal/d low-energy density diet, prepackaged foods that are gradually replaced with normal foods, and increased physical activity to promote weight loss. When the data were analyzed by last week of attendance, the JumpstartMD patients lost more kg weight than the 60,164 Platinum patients during weeks 1–4 (110% more), 5–13 (32%), 14–26 (36%), 27–39 (38%), and weeks 40–52 (13% more) . JumpstartMD % weight losses were 49% greater than the LOCF weight losses reported by Martin et al. for the Platinum Plan and 30% greater than the more current Rewards Plan  (Figure 16).
The largest meal replacement program in the United States is Nutrisystem. JumpstartMD weight loss was 18% to 30% greater than that reported for Nutrisystem by Cook et al. . A poster presentation on completers by Fabricatore et al. reported on 103,693 self-reported weights at 3 months and 32,280 self-reported weights at 6 months . JumpstartMD kg weight loss was 18% greater at 3 months and 9% greater after 6 months (Figure 11); however, these percentages may underestimate the true differences given that unsuccessful weight loss would likely discourage participation in the Nutrisystem optional online website. Indeed, Johnston et al. reported that Weight Watcher patients who made greater use of their online website were 3.1-fold more likely to reach 5% weight loss after 6 months and 5.4-fold more likely to achieve 10% weight loss than low-use patients . We expect this probably largely reflects self-selection of high-adherence to the Weight Watchers program given that simply recording weight produces minimal weight loss [25, 44, 45, 47]. JumpstartMD weight losses were somewhat smaller than those reported by Coleman et al. for Medifast [28, 29] and by Furlow et al. for Health Management Resources .
Unexpectedly, phentermine and phendimetrazine had, at best, a modest weight loss effect in the context of the low-calorie low-carbohydrate diet and behavioral intervention, perhaps because it is not a central part of the medically supervised lifestyle modification program and not central to a participant’s success. Its principal benefit was prolonging exposure to the weight loss intervention leading to additional weight loss consistent with nonpharmacologically treated patients.
Although participants tracked their diets using supplied forms or their own mobile phone software and shared this information with their health coach, these data were not collected for data analysis. Thus, there is no statistical verification of their carbohydrate intake or dietary caloric deficit. The superiority of JumpstartMD vis-à-vis other commercial programs does not exclude the possibility that patients choosing JumpstartMD may be more predisposed to weight loss (i.e., self-selection). Comparisons between JumpstartMD and other programs may be somewhat skewed by the fact that JumpstartMD participants could afford to pay $350 to $400 per month and the costs associated with a healthy low-carbohydrate diet and physical activity. Monthly pricing often diminished after 4 months on program because members had an option to transition from a weekly to a twice monthly for weight loss or maintenance or later for a monthly visit structure at a lower monthly fee for maintenance only. We do not have information on the income levels or health literacy of the JumpstartMD population, which could contribute to weight loss differences of the figures. The data available for statistical analyses also lacked detailed medical record information; however, medical histories were collected and reviewed by the clinical staff and adjustment made to the dietary prescription as appropriate. Although a low-carbohydrate intake was generally prescribed, the exact carbohydrate goals varied by participant in accordance with their weekly clinical assessments and interviews to judge the patient’s tolerance to the diet. Eliminating the possible effects of self-selection would require a randomized trial, an approach that has largely failed to distinguish weight loss differences between other commercial programs [33, 37, 42, 68]. We also caution that these analyses rely on previously published reports, which may not necessarily represent current practices in other commercial programs.
JumpstartMD appears to provide greater weight loss than most other published commercial programs (i.e., Weight Watchers, Slimming World, Rosemary Conley, Jenny Craig, and Nutrisystem), presumably because it provides resources necessary for comprehensive individualized nutritional and behavioral counseling in a medically supervised environment and because the low-carbohydrate dietary approach may promote greater satiety and voluntary limitation of caloric intake . Increased protein intake associated with a low-carbohydrate diet may also have contributed to increased satiety . Accessibility to the JumpstartMD program is dependent upon financial resources. It addresses the weight loss needs of those patients requiring or desiring greater personal attention than provided in less-expensive group instruction or online programs. Commercial weight loss programs offer a spectrum of personal support. Programs like Weight Watchers and Slimming World would be more easily scaled to address the weight loss needs of sizable overweight population at lower socioeconomic status. In addition, programs such as Weight Watchers may provide more pounds lost per dollar spent . However, JumpstartMD may be a better option for those valuing high touch, individualized attention and greater total weight loss combined with the associated health and aesthetic benefits. Moreover, pounds per dollar spent may be too narrow a criterion given that obese patients incur 46% higher inpatient costs, 27% more physician visits and outpatient costs, and 80% higher prescription costs than normal weight individuals .
The data are not publicly available. Dr Bourke will consider reasonable requests for access to the data.
Conflicts of Interest
Dr. Bourke is the Chief Medical Officer for JumpstartMD. Dr. Williams was commissioned to perform the analysis and assist in manuscript preparation but has no other financial interest in the research or conclusions. Dr. Williams takes responsibility for the analyses performed. Dr. Morton has no financial interest to disclose.
This research was supported by JumpstartMD.
- Centers for Disease Control and Prevention, Obesity and Overweight, FastStats Homepage, Centers for Disease Control and Prevention, Atlanta, GA, USA, 2018, https://www.cdc.gov/nchs/fastats/obesity-overweight.htm.
- I. Santos, F. F. Sniehotta, M. M. Marques, E. V. Carraça, and P. J. Teixeira, “Prevalence of personal weight control attempts in adults: a systematic review and meta-analysis,” Obesity Reviews, vol. 18, no. 1, pp. 32–50, 2017.
- S. Klein, L. E. Burke, G. A. Bray et al., “Clinical implications of obesity with specific focus on cardiovascular disease,” Circulation, vol. 110, no. 18, pp. 2952–2967, 2004.
- Prospective Studies Collaboration, “Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies,” The Lancet, vol. 373, no. 9669, pp. 1083–1096, 2009.
- IBISWorld, Weight Loss Services in the U.S. Industry Market Research Report; June 2014, IBISWorld, Los Angeles, CA, USA, 2014, http://clients1.ibisworld.com/reports/us/industry/default.aspx?entid=1719.
- S. A. Jebb, A. L. Ahern, A. D. Olson et al., “Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial,” The Lancet, vol. 378, no. 9801, pp. 1485–1492, 2011.
- J. Hartmann-Boyce, D. J. Johns, S. A. Jebb, C. Summerbell, and P. Aveyard, “Behavioural weight management programmes for adults assessed by trials conducted in everyday contexts: systematic review and meta-analysis,” Obesity Reviews, vol. 15, no. 11, pp. 920–932, 2014.
- S. Heshka, J. W. Anderson, R. L. Atkinson et al., “Weight loss with self-help compared with a structured commercial program,” JAMA, vol. 289, no. 14, pp. 1792–1798, 2003.
- C. M. Cook, C. N. McCormick, M. Knowles, and V. N. Kaden, “A commercially available portion-controlled diet program is more effective for weight loss than a self-directed diet: results from a randomized clinical trial,” Frontiers in Nutrition, vol. 4, 2017.
- J. M. Nicklas, K. W. Huskey, R. B. Davis, and C. C. Wee, “Successful weight loss among obese U.S. adults,” American Journal of Preventive Medicine, vol. 42, no. 5, pp. 481–485, 2012.
- A. L. Ahern, A. D. Olson, L. M. Aston, and S. A. Jebb, “Weight Watchers on prescription: an observational study of weight change among adults referred to Weight Watchers by the NHS,” BMC Public Health, vol. 11, pp. 434–438, 2011.
- K. J. L. Dixon, S. Shcherba, and R. R. Kipping, “Weight loss from three commercial providers of NHS primary care slimming on referral in North Somerset: service evaluation,” Journal of Public Health, vol. 34, no. 4, pp. 555–561, 2012.
- C. D. Madigan, A. J. Daley, A. L. Lewis, K. Jolly, and P. Aveyard, “Which weight-loss programmes are as effective as Weight Watchers?” British Journal of General Practice, vol. 64, no. 620, pp. e128–e136, 2014.
- N. S. Mitchell, M. C. Ellison, J. O. Hill, and A. G. Tsai, “Evaluation of the effectiveness of making weight Watchers available to Tennessee Medicaid (TennCare) recipients,” Journal of General Internal Medicine, vol. 28, no. 1, pp. 12–17, 2013.
- A. Avery, S. C. Langley-Evans, M. Harrington, and J. A. Swift, “Setting targets leads to greater long-term weight losses and “unrealistic” targets increase the effect in a large community-based commercial weight management group,” Journal of Human Nutrition and Dietetics, vol. 29, no. 6, pp. 687–696, 2016.
- A. Avery and L. Morris, “Making every contact count: the potential role of healthy living pharmacies in weight management,” Perspectives in Public Health, vol. 137, no. 4, pp. 203–205, 2017.
- C. Bye, A. Avery, and J. Lavin, “Tackling obesity in men-preliminary evaluation of men-only groups within a commercial slimming organization,” Journal of Human Nutrition and Dietetics, vol. 18, no. 5, pp. 391–394, 2005.
- J. H. Lavin, A. Avery, S. M. Whitehead et al., “Feasibility and benefits of implementing a slimming on referral service in primary care using a commercial weight management partner,” Public Health, vol. 120, no. 9, pp. 872–881, 2006.
- A. Lloyd and R. Khan, “Evaluation of healthy choices: a commercial weight loss programme commissioned by the NHS,” Perspectives in Public Health, vol. 131, no. 4, pp. 177–183, 2011.
- R. J. Stubbs, C. Pallister, S. Whybrow, A. Avery, and J. Lavin, “Weight outcomes audit for 34,271 adults referred to a primary care/commercial weight management partnership scheme,” Obesity Facts, vol. 4, pp. 113–120, 2011.
- R. J. Stubbs, D. J. Brogelli, C. J. Pallister, S. Whybrow, A. J. Avery, and J. H. Lavin, “Attendance and weight outcomes in 4754 adults referred over 6 months to a primary care/commercial weight management partnership scheme,” Clinical Obesity, vol. 2, no. 1-2, pp. 6–14, 2012.
- R. J. Stubbs, L. Morris, C. Pallister, G. Horgan, and J. H. Lavin, “Weight outcomes audit in 1.3 million adults during their first 3 months’ attendance in a commercial weight management programme,” BMC Public Health, vol. 15, p. 882, 2015.
- C. E. Finley, C. E. Barlow, F. L. Greenway, C. L. Rock, B. J. Rolls, and S. N. Blair, “Retention rates and weight loss in a commercial weight loss program,” International Journal of Obesity, vol. 31, no. 2, pp. 292–298, 2007.
- C. K. Martin, L. Talamini, A. Johnson, A. M. Hymel, and O. Khavjou, “Weight loss and retention in a commercial weight-loss program and the effect of corporate partnership,” International Journal of Obesity, vol. 34, no. 4, pp. 742–750, 2010.
- M. J. Hutchesson, C. E. Collins, P. J. Morgan, and R. Callister, “An 8-week web-based weight loss challenge with celebrity endorsement and enhanced social support: observational study,” Journal of Medical Internet Research, vol. 15, no. 7, p. e129, 2013.
- E. Hemmingsson, K. Johansson, J. Eriksson, J. Sundström, M. Neovius, and C. Marcus, “Weight loss and dropout during a commercial weight-loss program including a very-low-calorie diet, a low-calorie diet, or restricted normal food: observational cohort study,” The American Journal of Clinical Nutrition, vol. 96, no. 5, pp. 953–961, 2012.
- C. Meffert and N. Gerdes, “Program adherence and effectiveness of a commercial nutrition program: the metabolic balance study,” Journal of Nutrition and Metabolism, vol. 2010, Article ID 197656, 8 pages, 2010.
- C. Coleman, J. Kiel, A. Hanlon-Mitola, C. Sonzone, N. Fuller, and L. Davis, “Use of the Medifast meal replacement program for weight loss in overweight and obese clients: a retrospective chart review of three Medifast weight control centers (MWCC),” Food and Nutrition Sciences, vol. 3, no. 10, pp. 1433–1444, 2012.
- C. D. Coleman, J. R. Kiel, A. H. Mitola, J. S. Langford, K. N. Davis, and L. M. Arterburn, “Effectiveness of a Medifast meal replacement program on weight, body composition and cardiometabolic risk factors in overweight and obese adults: a multicenter systematic retrospective chart review study,” Nutrition Journal, vol. 14, no. 1, p. 77, 2015.
- E. A. Furlow and J. W. Anderson, “A systematic review of targeted outcomes associated with a medically supervised commercial weight-loss program,” Journal of the American Dietetic Association, vol. 109, no. 8, pp. 1417–1421, 2009.
- A. L. Ahern, G. M. Wheeler, P. Aveyard et al., “Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial,” The Lancet, vol. 389, no. 10085, pp. 2214–2225, 2017.
- L. Aston, M. Chatfield, and S. Jebb, Weight Change of Participants in the Weight Watchers GP Referral Scheme, MRC Human Nutrition Research, Cambridge, UK, 2007, https://signup.weightwatchers.co.uk/images/2057/dynamic/articles/2010/02/WWreferraldatareport.pdf.
- C. Baetge, C. P. Earnest, B. Lockard et al., “Efficacy of a randomized trial examining commercial weight loss programs and exercise on metabolic syndrome in overweight and obese women,” Applied Physiology, Nutrition, and Metabolism, vol. 42, no. 2, pp. 216–227, 2017.
- M. L. Dansinger, J. A. Gleason, J. L. Griffith, H. P. Sleker, and E. J. Schaefer, “Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial,” JAMA, vol. 293, pp. 45–53, 2005.
- S. Heshka, F. Greenway, J. W. Anderson et al., “Self-help weight loss versus a structured commercial program after 26 weeks: a randomized controlled study,” The American Journal of Medicine, vol. 109, no. 4, pp. 282–287, 2000.
- C. A. Johnston, S. Rost, K. Miller-Kovach, J. P. Moreno, and J. P. Foreyt, “A randomized controlled trial of a community-based behavioral counseling program,” The American Journal of Medicine, vol. 126, pp. 1143.e19–1143.e24, 2013.
- K. Jolly, A. Lewis, J. Beach et al., “Comparison of range of commercial or primary care led weight reduction programmes with minimal intervention control for weight loss in obesity: lighten up randomised controlled trial,” BMJ, vol. 343, no. 2, p. d6500, 2011.
- A. Luszczynska, A. Sobczyk, and C. Abraham, “Planning to lose weight: randomized controlled trial of an implementation intention prompt to enhance weight reduction among overweight and obese women,” Health Psychology, vol. 26, no. 4, pp. 507–512, 2007.
- D. G. Marrero, K. N. B. Palmer, E. O. Phillips, K. Miller-Kovach, G. D. Foster, and C. K. Saha, “Comparison of commercial and self-initiated weight loss programs in people with prediabetes: a randomized control trial,” American Journal of Public Health, vol. 106, no. 5, pp. 949–956, 2016.
- P. M. O’Neil, K. R. Theim, A. Boeka, G. Johnson, and K. Miller-Kovach, “Changes in weight control behaviors and hedonic hunger during a 12-week commercial weight loss program,” Eating Behaviors, vol. 13, no. 4, pp. 354–360, 2012.
- A. M. Pinto, J. L. Fava, D. A. Hoffmann, and R. R. Wing, “Combining behavioral weight loss treatment and a commercial program: a randomized clinical trial,” Obesity, vol. 21, no. 4, pp. 673–680, 2013.
- H. Truby, S. Baic, A. deLooy et al., “Randomised controlled trial of four commercial weight loss programmes in the UK: initial findings from the BBC “diet trials”,” BMJ, vol. 332, no. 7553, pp. 1309–1314, 2006.
- P. Aveyard, A. Lewis, S. Tearne et al., “Screening and brief intervention for obesity in primary care: a parallel, two-arm, randomised trial,” The Lancet, vol. 388, no. 10059, pp. 2492–2500, 2016.
- C. E. Collins, P. J. Morgan, P. Jones et al., “A 12-week commercial web-based weight-loss program for overweight and obese adults: randomized controlled trial comparing basic versus enhanced features,” Journal of Medical Internet Research, vol. 14, no. 2, p. e57, 2012.
- C. E. Collins, P. J. Morgan, M. J. Hutchesson, and R. Callister, “Efficacy of standard versus enhanced features in a web-based commercial weight-loss program for obese adults, part 2: randomized controlled trial,” Journal of Medical Internet Research, vol. 15, no. 7, p. e140, 2013.
- B. C. Gold, S. Burke, S. Pintauro, P. Buzzell, and J. Harvey-Berino, “Weight loss on the web: a pilot study comparing a structured behavioral intervention to a commercial program,” Obesity, vol. 15, no. 1, p. 155, 2007.
- L. G. Womble, T. A. Wadden, B. G. McGuckin, S. L. Sargent, R. A. Rothman, and E. S. Krauthamer-Ewing, “A randomized controlled trial of a commercial internet weight loss program,” Obesity Research, vol. 12, no. 6, pp. 1011–1018, 2004.
- C. L. Rock, B. Pakiz, S. W. Flatt, and E. L. Quintana, “Randomized trial of a multifaceted commercial weight loss program,” Obesity, vol. 15, no. 4, pp. 939–949, 2007.
- C. L. Rock, S. W. Flatt, N. E. Sherwood, N. Karanja, B. Pakiz, and C. A. Thomson, “Effect of a free prepared meal and incentivized weight loss program on weight loss and weight loss maintenance in obese and overweight women,” JAMA, vol. 304, no. 16, pp. 1803–1810, 2010.
- C. L. Rock, S. W. Flatt, B. Pakiz et al., “Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: a randomized controlled trial,” Diabetes Care, vol. 37, no. 6, pp. 1573–1580, 2014.
- A. N. Fabricatore, B. P. Daggy, and Y. Xiang, “Results not typical? Subjective and objective success in a commercial weight loss program,” in Proceedings of the Annual Scientific Meeting of the Obesity Society, Orlando, FL, USA, October 2011.
- G. D. Foster, K. E. Borradaile, S. S. Vander Veur et al., “The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study,” Postgraduate Medicine, vol. 121, no. 5, pp. 113–118, 2009.
- A. Figueroa, F. Vicil, M. A. Sanchez-Gonzalez et al., “Effects of diet and/or low-intensity resistance exercise training on arterial stiffness, adiposity, and lean mass in obese postmenopausal women,” American Journal of Hypertension, vol. 26, no. 3, pp. 416–423, 2013.
- L. M. Davis, C. Coleman, J. Kiel et al., “Efficacy of a meal replacement diet plan compared to a food-based diet plan after a period of weight loss and weight maintenance: a randomized controlled trial,” Nutrition Journal, vol. 9, no. 1, 2010.
- C. P. Moldovan, A. J. Weldon, N. S. Daher et al., “Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings,” Obesity, vol. 24, no. 11, pp. 2344–2350, 2016.
- J. M. Shikany, A. S. Thomas, T. M. Beasley, C. E. Lewis, and D. B. Allison, “Randomized controlled trial of the Medifast 5 & 1 Plan for weight loss,” International Journal of Obesity, vol. 37, no. 12, pp. 1571–1578, 2013.
- J. W. Anderson, L. R. Reynolds, H. M. Bush, J. L. Rinsky, and C. Washnock, “Effect of a behavioral/nutritional intervention program on weight loss in obese adults: a randomized controlled trial,” Postgraduate Medicine, vol. 123, no. 5, pp. 205–213, 2011.
- J. E. Donnelly, B. K. Smith, L. Dunn et al., “Comparison of a phone vs clinic approach to achieve 10% weight loss,” International Journal of Obesity, vol. 31, pp. 1270–1276, 2007.
- B. K. Smith, E. L. Van Walleghen, G. Cook-Wiens et al., “Comparison of two self-directed weight loss interventions: limited weekly support vs. no outside support,” Obesity Research & Clinical Practice, vol. 3, no. 3, pp. 149–157, 2009.
- D. D. Mellor, C. Whitham, S. Goodwin, M. Morris, M. Reid, and S. L. Atkin, “Weight loss in a UK commercial all meal provision study: a randomised controlled trial,” Journal of Human Nutrition and Dietetics, vol. 27, no. 4, pp. 377–383, 2014.
- K. A. Gudzune, R. S. Doshi, A. K. Mehta et al., “Efficacy of commercial weight-loss programs,” Annals of Internal Medicine, vol. 162, no. 7, pp. 501–512, 2015.
- L. M. Nackers, K. M. Ross, and M. G. Perri, “The association between rate of initial weight loss and long-term success in obesity treatment: does slow and steady win the race?” International Journal of Behavioral Medicine, vol. 17, no. 3, pp. 161–167, 2010.
- M. G. Perri, “The maintenance of treatment effects in the long-term management of obesity,” Clinical Psychology: Science and Practice, vol. 5, no. 4, pp. 526–543, 1998.
- Food and Drug Administration, Guidance for Industry Developing Products for Weight Management, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Washington, DC, USA, 2007, https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf.
- G. D. Foster, T. A. Wadden, R. A. Vogt, and G. Brewer, “What is a reasonable weight loss? Patients’ expectations and evaluations of obesity treatment outcomes,” Journal of Consulting and Clinical Psychology, vol. 65, no. 1, pp. 79–85, 1997.
- C. E. Lewis, D. R. Jacobs, H. McCreath et al., “Weight gain continues in the 1990s: 10-year trends in weight and overweight from the CARDIA study,” American Journal of Epidemiology, vol. 151, no. 12, pp. 1172–1181, 2000.
- D. F. Williamson, H. S. Kahn, and T. Byers, “The 10-y incidence of obesity and major weight gain in black and white US women aged 30–55 y,” The American Journal of Clinical Nutrition, vol. 53, no. 6, pp. 1515S–1518S, 1991.
- A. G. Tsai and T. A. Wadden, “Systematic review: an evaluation of major commercial weight loss programs in the United States,” Annals of Internal Medicine, vol. 142, no. 1, pp. 56–66, 2005.
- M. Porrini, A. Santangelo, R. Crovetti, P. Riso, G. Testolin, and J. E. Blundell, “Weight, protein, fat, and timing of preloads affect food intake,” Physiology & Behavior, vol. 62, no. 3, pp. 563–570, 1997.
- M. S. Westerterp-Plantenga, A. Nieuwenhuizen, D. Tomé, S. Soenen, and K. R. Westerterp, “Dietary protein, weight loss, and weight maintenance,” Annual Review of Nutrition, vol. 29, no. 1, pp. 21–41, 2009.
- E. A. Finkelstein and E. Kruger, “Meta- and cost-effectiveness analysis of commercial weight loss strategies,” Obesity, vol. 22, no. 9, pp. 1942–1951, 2014.
- E. A. Finkelstein, J. G. Trogdon, J. W. Cohen, and W. Dietz, “Annual medical spending attributable to obesity: payer-and service-specific estimates,” Health Affairs, vol. 28, no. Supplement 1, pp. w822–w831, 2009.
Copyright © 2020 Sean Bourke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.